Slide 1: Orion Interim Report Q1/2013
Orion Interim Report Q1/2013 23 April 2013 Timo Lappalainen President & CEO
Slide 2: Forward-looking statements
This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of these strat
Slide 3: First quarter as anticipated
First quarter as anticipated • Net sales similar to comparative period of previous year • Operating profit slightly lower than in previous year as expected • In March Orion submitted a marketing authorisation application for a budesonide-formoterol combined formulation in the Easyhaler® product fami
Slide 4: Net sales and operating profit
Net sales and operating profit Group key figures Q1/2013 Q1/2012* Change % 2012* Net sales, EUR million 249 247 +1% 980 Operating profit, EUR million 74 79 -6% 278 Basic earnings per share, EUR 0.39 0.42 -6% 1.47 Cash flow per share before financial items, EUR 0.07 0.27 -74% 1.23 • Net sales similar
Slide 5: Breakdown of net sales
Breakdown of net sales By business divisions By market area Proprietary Products Specialty Products Finland Scandinavia Other Europe Animal Health Fermion North America Other Countries Contract manufacturing & Other Orion Diagnostica 6% 16% 4% 27% 6% 6% 40% 14% 13% 38% 30% 5 23 April 2013 Orion Inte
Slide 6: Business Reviews
Business Reviews
Slide 7: Pharmaceuticals business
Pharmaceuticals business Key figures for Pharmaceuticals business Q1/2013 Q1/2012* Change % 2012* Net sales of Pharmaceuticals, EUR million 234 233 +1% 929 Proprietary Products 100 99 +1% 404 Specialty Products 96 90 +6% 367 Animal Health 15 18 -19% 69 Fermion 13 16 -16% 48 Contract manufacturing an
Slide 8: Best-selling pharmaceuticals
Best-selling pharmaceuticals Orion’s best-selling pharmaceuticals, Business EUR million Division Q1/2013 Q1/2012 Change % 2012 1. Stalevo®, Comtess® and Comtan® (Parkinson’s disease) PP 60.3 63.2 -4.7% 250 2. Precedex® (intensive care sedative) PP 12.0 10.3 +16.3% 45 3. Simdax® (acute decompensated
Slide 9: Orion clear market leader in Finland
Orion clear market leader in Finland Finnish human pharmaceuticals Finland’s biggest pharmaceutical market in Q1/2013 companies in Q1/2013 • Wholesale EUR 497 million (+1%) EUR million 60 57 Orion in Finnish human 50 pharmaceuticals market • Sales growth 7% 40 30 32 • Orion clear market leader 28 30
Slide 10: Sales of Parkinson's drugs growing in Japan
Sales of Parkinson’s drugs growing in Japan Overall markets for Parkinson’s drugs Market shares of Orion’s January─December 2012 branded Parkinson’s drugs 2012 2011 Finland 2) 24% 24% • United States 3) USD 771 million (+8%) Sweden 2) 14% 14% • Five largest European markets 1) 3) EUR 963 million (+1
Slide 11: Precedex and dexdor growing strongly
Precedex and dexdor® growing strongly Markets for intensive care sedative Breakdown of Precedex Precedex January─December 2012 markets USD million 250 • Total USD 270 million (+31%) 200 • United States USD 213 million (+32%) 150 Sales of dexdor® intensive care 100 sedative January─December 2012 50 •
Slide 12: Key clinical pharmaceutical development projects
Key clinical pharmaceutical development projects Clinical phases Project Indication I II III Registration Easyhaler® budesonide-formoterol Asthma, COPD Easyhaler® salmeterol-fluticasone Asthma, COPD Stalevo® for Japanese markets 1) Parkinson’s disease ODM-101 Parkinson’s disease (more effective levo
Slide 13: Diagnostics business
Diagnostics business Key figures for Diagnostics business Q1/2013 Q1/2012* Change % 2012* Net sales, EUR million 16 16 +2% 54.1 Operating profit, EUR million 2.3 2.5 -8% 2.3 • QuikRead® tests remained main product – Sales of more user-friendly prefilled QuikRead 101 system and QuikRead go®, a new ge
Slide 14: Outlook for 2013
Outlook for 2013 • Net sales will be at similar level to 2012 (net sales in 2012 were EUR 980 million) • Operating profit will be slightly lower than in 2012 (operating profit in 2012 was EUR 278 million*) • Group’s capital expenditure will be about EUR 80 million excluding substantial corporate or
Slide 15: Orion Calendar
Orion Calendar • Interim Report January─June 2013 30 July 2013 • Interim Report January─September 2013 22 October 2013 • Capital Markets Day in Helsinki 20 November 2013 15 23 April 2013 Orion Interim Report Q1/2013
Slide 16: Slide 16
Slide 17: Orion's financial objectives
Orion’s financial objectives Orion’s financial objectives are: • Ensuring financial stability • Profitable growth The objectives are achieved through: • Increasing net sales. Achievement of this objective requires continuous investment in development of the product portfolio. • Maintaining profitabi
Slide 18: Key figures by quarter
Key figures by quarter* EUR million Net sales EUR million Operating profit 1200 300 283 278 980 254 1000 918 250 60 59 850 207 53 772 254 200 800 236 Q4 65 Q4 215 44 76 193 71 Q3 600 246 Q3 150 211 56 213 65 192 Q2 65 Q2 400 100 60 227 233 50 Q1 196 207 Q1 200 50 93 71 79 74 190 215 244 247 249 57 0
Slide 19: Key figures for 2009-Q1/2013
Key figures for 2009─Q1/2013 Orion’s key figures 2009 2010 2011 2012* Q1/2013 Q1/2012* Change % Net sales, EUR million 771.5 849.9 917.9 980.4 249.4 247.4 +0.8% Operating profit, EUR million 207.0 254.2 282.9 278.3 74.1 78.6 -5.7% Profit before taxes, EUR million 203.7 252.6 282.0 276.6 73.8 78.7 -6
Slide 20: Income Statement 2009-Q1/2013
Income Statement 2009─Q1/2013 Formation of profits, EUR million 2009 2010 2011 2012* Q1/2013 Q1/2012* Change % Net sales 771.5 849.9 917.9 980.4 249.4 247.4 +0.8% Cost of goods sold -265.2 -283.2 -305.1 -350.8 -91.8 -86.8 +5.8% Gross profit 506.3 566.8 612.8 629.6 157.6 160.6 -1.9% Other operating i
Slide 21: Main pharmaceutical development projects
Main pharmaceutical development projects • Expansion of Easyhaler® product family. Under development are new budesonide-formoterol and fluticasone- salmeterol combined formulations for treatment of asthma and COPD – Orion submitted the marketing authorisation application for the budesonide-formotero
Slide 22: Product protection situation of key products
Product protection situation of key products Key patents or data protection expire Molecule Product Indication Europe USA Japan Stalevo®, November 2012 Entacapone Parkinson’s disease October 2013 2) 2015 3) Comtess® and Comtan® October 2013 1) Acute Levosimendan Simdax® decompensated September 2015
Slide 23: Dividend distribution policy
Dividend distribution policy Dividend distribution history Dividend distribution policy EUR 1,40 140% 1,20 120% Orion’s dividend distribution takes into account distributable funds and capital 1,00 100% expenditure and other financial 0,80 80% requirements in medium and long term to achieve the fina
Slide 24: Orion - Building well-being
S RION ing well-being Buildi